MEDP's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 165.8 -- higher than 80.78% of US-listed equities with positive expected earnings growth.
Medpace Holdings Inc's stock had its IPO on August 11, 2016, making it an older stock than just 15.64% of US equities in our set.
With a year-over-year growth in debt of 140.47%, Medpace Holdings Inc's debt growth rate surpasses 90.9% of about US stocks.
Stocks with similar financial metrics, market capitalization, and price volatility to Medpace Holdings Inc are HCKT, PIPR, III, HLI, and CNS.
MEDP's SEC filings can be seen here. And to visit Medpace Holdings Inc's official web site, go to www.medpace.com.
Medpace, Inc. operates as a contract research organization that provides research based drug and medical device development services. The company was founded in 1992 and is based in Cincinnati, Ohio.
MEDP Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for MEDP, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Medpace Holdings Inc ranked in the 41th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Medpace Holdings Inc, consider:
The stock's equity weight, or the proportion of capital from equity relative to debt, is 98. Notably, its equity weight is greater than 81.8% of US equities in the Healthcare sector yielding a positive free cash flow.
The business' balance sheet suggests that 2% of the company's capital is sourced from debt; this is greater than only 10.73% of the free cash flow producing stocks we're observing.
Medpace Holdings Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -206.25. This coverage rate is greater than that of only 1.24% of stocks we're observing for the purpose of forecasting via discounted cash flows.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
QDEL, STE, AMGN, INBP, and NVS can be thought of as valuation peers to MEDP, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
ReportsnReports.com the exclusive leading provider of market research reports published research report on “China Contract Research Organization (CRO) Market (Clinical, Pre-clinical & Discovery): Insights, Trends and Forecast (2020-2024)”. China CRO market value is anticipated to reach US$27.04 billion in 2024, growing
Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August J. Troendle sold 185,219 shares of the firm’s stock in a transaction dated Thursday, January 7th. The shares were sold at an average price of $140.06, for a total transaction of $25,941,773.14. NASDAQ:MEDP traded up $1.86 during midday trading on Friday, hitting $141.76. 184,940 shares of the stock were […]
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its fourth quarter and fiscal year 2020 financial results after the market close on Monday, February 15, 2021. The Company will host a conference call the following morning, Tuesday, February 16, 2021, at 9:00 a.m. ET to discuss these results. To participate in the conference call, dial 800-219-7113 (domestic) or 574-990-1030 (international) using the passcode 9646903. To access th
Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August J. Troendle sold 3,547 shares of the firm’s stock in a transaction on Wednesday, December 23rd. The shares were sold at an average price of $140.11, for a total transaction of $496,970.17. Following the completion of the sale, the chief executive officer now owns 706,643 shares in the company, […]
The 800+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the third quarter, which unveil their equity positions as of September 30. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive […]